Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2089 | 7,8-Dihydroxyflavone | Tyrosine kinase receptor B (TrkB) agonist | €55.00 | |
| 1466 | A 769662 | AMPK activator | €85.00 | |
| 2389 | AICAR | Potent AMPK activator and inducer of differentiation of NSCs | €45.00 | |
| 2551 | Alda 1 | Small molecule activator of ALDH2 | €65.00 | |
| 2006 | Apoptosis Activator 2 | A cell-permeable apoptosis activator | €75.00 | |
| 3062 | AZD1656 | Glucokinase (GK) activator | €165.00 | |
| 2185 | BAM 7 | Selective small-molecule activator of proapoptotic BAX | €90.00 | |
| 2172 | BAY 58-2667 hydrochloride | Soluble, potent nitric oxide-independent guanylyl cyclase (sGC) activator | €125.00 | |
| 3431 | BTSA1 | Potent activator of proapoptotic BAX | €110.00 | |
| 2575 | C-DIM12 | Nurr1 activator that stimulates apoptosis in bladder cancer cells | €85.00 | |
| 1835 | CK 1827452 | Cardiac specific myosin ATPase activator | €115.00 | |
| 2841 | COTI-2 | Reactivator of mutant p53 | €125.00 | |
| 2264 | Forskolin | Activator of adenylate cyclase. Naturally occurring labdane diterpene | €90.00 | |
| 3262 | HEI3090 | Positive modulator of the P2X7 receptor | €130.00 | |
| 2021 | HL 010183 | Metformin derivative; AMPK activator | €135.00 | |
| 2484 | K6PC-5 | SphK1 (or SK1) activator that increases sphingosine-1-phosphate production | €105.00 | |
| 2425 | MHY 1485 | mTOR activator with an inhibitory effect on autophagy | €70.00 | |
| 2149 | Mitapivat |
Activator of pyruvate kinase isoenzyme M2 (PKM2) |
€110.00 | |
| 2641 | ML334 | Activator of NRF2 by inhibition of Keap1-NRF2 interactions | €130.00 | |
| 2703 | ML346 | Hsp70 activator | €125.00 | |
| 1941 | MLR 1023 | Selective allosteric activator of Lyn kinase | €95.00 | |
| 2565 | N106 | Activator of E1 ligase mediated SERCA2a SUMOylation | €95.00 | |
| 2955 | NSC 228155 | EGFR tyrosine kinase activator; Inhibitor of KIX-KID interaction | €75.00 | |
| 2016 | NSC 319726 | Reactivator of the p53 mutant p53R175 | €95.00 | |
| 2564 | NSC 59984 | Activator of p53 that restores WT p53 signaling via p73 activation | €95.00 | |
| 2497 | Omaveloxolone | Triterpenoid activator of NRF2 and inhibitor of NF-κB | €90.00 | |
| 3581 | ONC212 | TRAIL inducer; Selective GPR132 agonist | €110.00 | |
| 1743 | PAC 1 | Procaspase activating compound 1 | €80.00 | |
| 1659 | PS 48 | Allosteric activator of phosphoinositide-dependent protein kinase 1 (PDPK1) | €80.00 | |
| 3480 | PY-60 | Specific YAP activator targeting ANXA2 | €150.00 | |